$MRNA Watching 786 fib Nice cypher on MRNA, Do not care for the name but it can work.. I will post if get long
MRNA trade ideas
MRNA // 134.94 118.55 our support pointsWe need to hold on at 134.94. Our second support point is at 118.55. Those who want to buy from resistance should look for a wedge close in the daily timeframe . Pay attention to the wedge resistance in the weekly timeframe .
$MRNA What Up$MRNA started playing this since it was in the low $20s and then got rid of it at the start of this year. And IMO this is headed under $100. It will get a kick start when the next Pandemic happens and WHO rules lockdowns across the world. Regardless of the hype, I don't see any reason to take a position in this ticker. The only outcome is, EXIT for me :) Although it does have a promising technology but it will not be able to generate the kind of revenue it did with the Pandemic vax
MRNA | This is a BUY | BOUNCEModerna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
$MRNA with a bearish outlook following its earnings #StocksThe PEAD projected a bearish outlook for $MRNA after a negative under reaction following its earnings release placing the stock in drift D .
MRNA LONGOVERSOLD and previous support level are at $139-138. Buy and sell when it gets close to 200 MA (blue line) close to the $150-155 range.
Will test 180sIf breaks above 180 it can run to 260s midterm
If gets rejected at 180 will need to come back down and try to form a higher low
modernaI have no exact idea about this stock. it could move in either direction as it is holding - in the middle of both 20EMA&50MA. this is one of the best stocks to add watchlist but not opened a position yet. I will be back to this stock mid-next week after see monthly close on it
Possible Head and ShouldersPrice is above the neckline which is strong support until broken.
ES with the break of the neckline and a downtrend.
Short interest around 4%.
Earnings are estimated to be on 2-23.
A lot could depend on earnings.
No recommendation.
Short with clean break of the neckline.
TBox for MRNAConsolidation areas based on Price Action.
EMAs are not usefull at the moment with the price showing negative price action and a bearish setup.
About to dipPrice failed to break the $210 resistance and is going back down. It shouldn't take too long to fall, and maybe in a few weeks from now is going to try to break the $210 again, but not now.
Bearish trade idea on MRNAWe should continue lower to about 151 and some change and have a retest into about 165-170 -- Looking for a bearish play and roll over!
Moderna (MRNA) ... Time for a shot in the Arm ?Moderna (MNRA). This is a potential long trade if it reaches my area of interest in my PRZ (price reversal zone).
A nicely formed ABCD formation together with a Harmonic Crab / Alternate Bat (depending where X starts), come together in the mid to low $160s.
(This also happens to come full circle to the recent December 2022 low.)
This together with positive momentum hopefully sets up one or both of the targets objectives.
I wouldn't chase this and beware of broader markets.
Earnings are expected Feb. 23rd at $4.70.
As always DYODD.
I will monitor
S,
mrnathe stock name is mrna which means to die, and the ema crossover suggests so, when the emas crossover like they have crossed over right now it is known as mini maharaja death crossover, so short
MRNAModerna shows 145 or 115 as a target on the short side..
Building a very good base up here or it's preparing to break below 115 to target 80$.
Nonetheless been short since 210/share.
MRNA Short$MRNA in the ol wedge formation is going to send this thing down to the low 100's at least.
U.S. no longer in a pandemic will send the company earnings to doo doo once more.
$MRNA - Moderna Short Thesis 2-8-2023$MRNA - Moderna breaking down. 50MA sloping down. Wave 3 of 5 Down Waves. See notations in chart. Just a technical thesis. Not investment advice...
Bullish Crossover for MRNA Share Appears in the HorizonModerna's share (MRNA) price has been running in a narrow price range since November 8 after a series of gains extending since October 21, surpassing the short and long-term exponential moving averages in a positive short-term sign. Meanwhile, an unclear zigzag path has dominated MRNA share since the beginning of the year.
As for now, and on the daily chart, we keep an eye on 180.13 and $198.82 as possible bullish targets, as we await the bullish crossover of the MA-25 and MA-50 to achieve the possible bullish path.
On the flip side, if MRNA share price fails to stabilize above the $162 level, the previous bullish hypothesis may be invalidated, and we may witness a pullback towards $142-135 levels (yellow shaded area).
MRNA MOONDERNA INC COMShowed up on Stikstockitslive properietary scanner. Decent entry risk managing leaving room for < 150. Decent short term entry here RSI BLUE LINING.
STIKSTOCKITSLIVE
The HERCULES portfolioIt's time to keep a close eye on HERCULES portfolio stocks to be ready to reposition once the rules I've outlined in my post “A trading system for rookies” are met.
I also urge you to consider positions in the Greek Stock Exchange where there are now many reliable and safe stocks that are in a mature phase of rise.
Some of them are presented below. For more information you can search the recent reports of major investment houses Morgan Stanley, JP Morgan and others.
Also take a look at my post “Is the Greek stock market ready to skyrocket?”.
Never EasyCup & Handle
This broke out and experienced a throwback.
The throwback sent it back down to below long entry level.
Volatile but we trade at our own risk.
It does seem this is a stock one should slip in and out of, collect profit and move on, but who knows?
Throwbacks differ from pull backs. Pull backs are natural and are considered healthy.
Throwbacks can hurt performance and occur when a security has issues holding on to the break out price and throw back to beneath the long entry level in a quick manner.
No recommendation.
This does look like a CUP with a rounded bottom and does not have a pointy W at the bottom of the cup that I can see. Any pattern can fail/price is just below the .618 of the trend up.
